Pfizer/Eyetech Sets Sights On Diabetic Macular Edema For Macugen Sales Growth
This article was originally published in The Pink Sheet Daily
Executive Summary
Eyetech and Pfizer will initiate a Phase II/III pivotal trial during the second half of the year, Eyetech said. The age-related macular degeneration market, for which Macugen is currently approved, may face increasing competition
You may also be interested in...
Genentech's Lucentis BLA Will Not Include Data Supporting Dosing Advantage
FDA denies fast-track designation for the wet age-related macular degeneration product; the company plans to keep the filing on track and submit the more flexible dosing data from its PIER trial in an sBLA.
Genentech's Lucentis BLA Will Not Include Data Supporting Dosing Advantage
FDA denies fast-track designation for the wet age-related macular degeneration product; the company plans to keep the filing on track and submit the more flexible dosing data from its PIER trial in an sBLA.
Eyetech To Become Full OSI Subsidiary Under $935 Mil. Deal
OSI's acquisition of Macugen developer Eyetech will pit the company against its Tarceva partner Genentech in the macular degeneration market.